SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-043757
Filing Date
2024-11-06
Accepted
2024-11-06 08:05:59
Documents
15
Period of Report
2024-10-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 57143
2 ex99-1.htm EX-99.1 17349
3 ex99-1_001.jpg GRAPHIC 24994
  Complete submission text file 0001493152-24-043757.txt   293003

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE evfm-20241031.xsd EX-101.SCH 3009
5 XBRL LABEL FILE evfm-20241031_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE evfm-20241031_pre.xml EX-101.PRE 24161
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3587
Mailing Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130
Business Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130 (858) 550-1900
Evofem Biosciences, Inc. (Filer) CIK: 0001618835 (see all company filings)

IRS No.: 208527075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36754 | Film No.: 241429316
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)